Department of Physical Medicine and Rehabilitation, Kocaeli Government Hospital, Gunes Street, 41300 Kocaeli, Turkey.
Department of Cardiology, Kocaeli Government Hospital, Gunes Street, 41300 Kocaeli, Turkey.
J Stroke Cerebrovasc Dis. 2021 Mar;30(3):105580. doi: 10.1016/j.jstrokecerebrovasdis.2020.105580. Epub 2020 Dec 30.
Inflammation plays an important role in the development of atherosclerotic vascular disease, which is the leading cause of morbidity and mortality in the adult population. Several clinical trials have shown that suppression of the inflammatory response can delay or decrease the atherosclerotic process. The aim of this study was to investigate carotid intima-media thickness (CIMT) between patients with chronic disease history plus gout using colchicine and patients with cardiovascular risk factors.
In total, 102 patients (85 female, 17 male) were included. There were two groups in the study: Group 1 - patients with chronic diseases including cardiovascular risk factors plus gout using colchicine (0,5 mg twice a day); and Group 2 - patients with chronic diseases including cardiovascular risk factors only. All patients underwent ultrasonography for the measurement of CIMT. Additionally, the serum concentrations of C-reactive protein (CRP) and the levels of lipids such as cholesterol, triglyceride, LDL, HDL were measured.
The mean age of patients was 62.35±6.68 years and 64.27±5.32 years in Group 1 and Group 2, respectively. There was also no statistically significant difference in the levels of lipids between groups (p>0.05). The value of CIMT and CRP in Group 1 and Group 2 were 0.98±0.20 and 0.26±0.14, 1.18±0.15 and 0.58±0.42, respectively. There was a statistically significant difference between groups (p<0.05). The colchicine group was found to have a statistically significant lowering of CIMT and CRP compared to the non-colchicine group.
It appears that colchicine in addition to statins and other standard treatments is an effective treatment for the interception of cardiovascular and cerebrovascular events in patients with cardiovascular risk factors.
炎症在动脉粥样硬化性血管疾病的发展中起着重要作用，该病是成年人发病率和死亡率的主要原因。几项临床试验表明，抑制炎症反应可以延缓或减少动脉粥样硬化过程。本研究旨在探讨伴有慢性病史（包括心血管危险因素和痛风）并使用秋水仙碱的患者与伴有心血管危险因素的患者之间的颈动脉内膜中层厚度（CIMT）差异。
共纳入 102 例患者（85 例女性，17 例男性）。研究分为两组：组 1 - 伴有慢性疾病（包括心血管危险因素和痛风）并使用秋水仙碱（0.5mg，每日两次）的患者；组 2 - 伴有慢性疾病（包括心血管危险因素）但未使用秋水仙碱的患者。所有患者均接受超声检查以测量 CIMT。此外，还测量了血清 C-反应蛋白（CRP）浓度和胆固醇、甘油三酯、LDL、HDL 等血脂水平。
患者的平均年龄分别为 62.35±6.68 岁和 64.27±5.32 岁，组间血脂水平无统计学差异（p>0.05）。组 1 和组 2 的 CIMT 和 CRP 值分别为 0.98±0.20 和 0.26±0.14、1.18±0.15 和 0.58±0.42，组间有统计学差异（p<0.05）。与非秋水仙碱组相比，秋水仙碱组的 CIMT 和 CRP 明显降低。
除他汀类药物和其他标准治疗外，秋水仙碱似乎也是心血管危险因素患者预防心脑血管事件的有效治疗方法。
